Unknown

Dataset Information

0

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.


ABSTRACT: Vascular disrupting agents (VDAs) represent a novel approach to the treatment of cancer, resulting in the collapse of tumor vasculature and tumor death. 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise mechanism of action is unknown despite extensive preclinical and clinical investigations. Our data demonstrate that DMXAA is a novel and specific activator of the TANK-binding kinase 1 (TBK1)-interferon (IFN) regulatory factor 3 (IRF-3) signaling pathway. DMXAA treatment of primary mouse macrophages resulted in robust IRF-3 activation and approximately 750-fold increase in IFN-beta mRNA, and in contrast to the potent Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS), signaling was independent of mitogen-activated protein kinase (MAPK) activation and elicited minimal nuclear factor kappaB-dependent gene expression. DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and IRF-3 but was myeloid differentiation factor 88-, Toll-interleukin 1 receptor domain-containing adaptor inducing IFN-beta-, IFN promoter-stimulator 1-, and inhibitor of kappaB kinase-independent, thus excluding all known TLRs and cytosolic helicase receptors. DMXAA pretreatment of mouse macrophages induced a state of tolerance to LPS and vice versa. In contrast to LPS stimulation, DMXAA-induced IRF-3 dimerization and IFN-beta expression were inhibited by salicylic acid. These findings detail a novel pathway for TBK1-mediated IRF-3 activation and provide new insights into the mechanism of this new class of chemotherapeutic drugs.

SUBMITTER: Roberts ZJ 

PROVIDER: S-EPMC2118649 | BioStudies | 2007-01-01

REPOSITORIES: biostudies

Similar Datasets

2008-06-15 | E-GEOD-7194 | ArrayExpress
2009-01-01 | S-EPMC2796624 | BioStudies
1000-01-01 | S-EPMC1933404 | BioStudies
2003-01-01 | S-EPMC2194210 | BioStudies
2019-01-01 | S-EPMC6512007 | BioStudies
2010-01-01 | S-EPMC2888425 | BioStudies
2005-01-01 | S-EPMC1276050 | BioStudies
2010-01-01 | S-EPMC2836049 | BioStudies
1000-01-01 | S-EPMC2710658 | BioStudies
2013-01-01 | S-EPMC3702631 | BioStudies